Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice

JOURNAL OF CONTROLLED RELEASE

卷:172

Review

Stirland, Darren Lars¹  Nichols, Joseph W.¹  Miura, Seiji^2,3  Bae, You Han³ 

[1] Univ Utah, Coll Engn, Dept Bioengn, Salt Lake City, UT 84112 USA

[2] Kowa Co Ltd, Fuji Res Labs, Div Pharmaceut, Fuji, Shizuoka, Japan

[3] Univ Utah, Coll Pharm, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA

关键词: Cancer therapy;    Drug carrier;    Nanomedicine;    Drug delivery;    Clinical translation;   

DOI  :  10.1016/j.jconrel.2013.09.026

来源: Elsevier

【 摘 要 】

With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil (R), PK1, Abraxane (R), Genexol-PM (R), Xyotax (TM), NC-6004, Mylotarg (R), PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold. (C) 2013 Elsevier B.V. All rights reserved.

【 授权许可】

Free